JP6240067B2 - 光感受性キメラｇｐｃｒタンパク質 - Google Patents

光感受性キメラｇｐｃｒタンパク質 Download PDF

Info

Publication number
JP6240067B2
JP6240067B2 JP2014516148A JP2014516148A JP6240067B2 JP 6240067 B2 JP6240067 B2 JP 6240067B2 JP 2014516148 A JP2014516148 A JP 2014516148A JP 2014516148 A JP2014516148 A JP 2014516148A JP 6240067 B2 JP6240067 B2 JP 6240067B2
Authority
JP
Japan
Prior art keywords
protein
mglur6
chimeric
pharmaceutical composition
gpcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014516148A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014524903A (ja
JP2014524903A5 (enExample
Inventor
バン・ワイク，ミチール
クレインロジェル，ソンジャ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arctos Medical AG
Original Assignee
Haag Streit Medtech AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haag Streit Medtech AG filed Critical Haag Streit Medtech AG
Publication of JP2014524903A publication Critical patent/JP2014524903A/ja
Publication of JP2014524903A5 publication Critical patent/JP2014524903A5/ja
Application granted granted Critical
Publication of JP6240067B2 publication Critical patent/JP6240067B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/40—Fish
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Environmental Sciences (AREA)
  • Animal Husbandry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2014516148A 2011-06-24 2012-06-22 光感受性キメラｇｐｃｒタンパク質 Active JP6240067B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161500863P 2011-06-24 2011-06-24
US61/500,863 2011-06-24
PCT/CH2012/000138 WO2012174674A1 (en) 2011-06-24 2012-06-22 Light-sensitive chimeric gpcr protein

Publications (3)

Publication Number Publication Date
JP2014524903A JP2014524903A (ja) 2014-09-25
JP2014524903A5 JP2014524903A5 (enExample) 2017-11-02
JP6240067B2 true JP6240067B2 (ja) 2017-11-29

Family

ID=46456289

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014516148A Active JP6240067B2 (ja) 2011-06-24 2012-06-22 光感受性キメラｇｐｃｒタンパク質

Country Status (19)

Country Link
US (1) US10112984B2 (enExample)
EP (2) EP3029063B1 (enExample)
JP (1) JP6240067B2 (enExample)
KR (1) KR102008538B1 (enExample)
CN (2) CN103814045B (enExample)
AU (1) AU2012272505B2 (enExample)
BR (2) BR112013033028A8 (enExample)
CA (1) CA2840458C (enExample)
DK (1) DK3029063T3 (enExample)
ES (1) ES2766398T3 (enExample)
HR (1) HRP20200004T1 (enExample)
HU (1) HUE047074T2 (enExample)
LT (1) LT3029063T (enExample)
PL (2) PL3029063T3 (enExample)
PT (1) PT3029063T (enExample)
RU (1) RU2637367C2 (enExample)
SI (1) SI3029063T1 (enExample)
WO (1) WO2012174674A1 (enExample)
ZA (1) ZA201308824B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140087463A1 (en) * 2012-09-25 2014-03-27 The Washington University Optical control of cell signaling
US9862970B2 (en) 2013-06-11 2018-01-09 Friedrich Miescher Institute For Biomedical Research Retinal on bipolar cells-specific artificial promoter
GB201403260D0 (en) 2014-02-25 2014-04-09 Univ Manchester Treatment of retinal degeneration using gene therapy
EP3535282A4 (en) * 2016-11-06 2020-04-08 Nanoscope Technologies LLC OPTOGENETIC MODULATION BY OPSINS WITH MULTIPLE CHARACTERISTICS FOR RESTORATION OF VISION AND OTHER ASSOCIATED APPLICATIONS
EP3318285A1 (en) * 2016-11-08 2018-05-09 Oxford University Innovation Limited Treatment of eye disease
BR112020009329A2 (pt) * 2017-11-13 2020-10-13 The Regents Of The University Of California composições e métodos para melhorar a função visual
EP3735572A1 (en) * 2018-01-02 2020-11-11 Signify Holding B.V. Light melanopic activity indicator
CA3314168A1 (en) * 2019-04-29 2026-08-05 Confo Therapeutics N.V. Screening methods and assays for use with transmembrane proteins, in particular with gpcrs
CN114729009A (zh) 2019-10-31 2022-07-08 伯尔尼大学 用于眼部基因递送的aav载体变体
KR20220111294A (ko) * 2019-11-29 2022-08-09 유니버시태트 베른 키메라 옵신 gpcr 단백질
WO2021140205A1 (en) * 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
CN112675293A (zh) * 2020-12-31 2021-04-20 吴伯骥 HrpNEcb蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用
CN114762723A (zh) * 2020-12-31 2022-07-19 吴伯骥 HrpZpst蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用
CA3252767A1 (en) * 2022-06-07 2023-12-14 Adverum Biotechnologies, Inc. VARIANTS OF MELANOPSINE FOR VISION RESTORATION
CN118791624B (zh) * 2023-04-11 2026-04-03 苏州星明优健生物技术有限公司 用于治疗视网膜神经退行性疾病的新型gpcr嵌合视蛋白
WO2026017073A1 (zh) * 2024-07-16 2026-01-22 北京脑科学与类脑研究所 一种光敏蛋白及其应用
CN120442622A (zh) * 2024-09-23 2025-08-08 中眸医疗科技(武汉)有限公司 多种在on型双极细胞上高效靶定的启动子在基因治疗技术中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005252A2 (en) * 1995-07-26 1997-02-13 Nps Pharmaceuticals, Inc. Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
AU2003249318A1 (en) 2002-07-18 2004-02-09 The General Hospital Corp. Method for augmenting vision in persons suffering from photoreceptor cell degeneration
GB0426196D0 (en) 2004-11-30 2004-12-29 Imp College Innovations Ltd Methods of treatment
US8470790B2 (en) * 2006-05-04 2013-06-25 Wayne State University Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
EP1891976A1 (en) 2006-08-23 2008-02-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute for Biomedical Research Use of light sensitive genes
US8178496B2 (en) * 2007-12-21 2012-05-15 The Regents Of The University Of California Photoreactive regulator of glutamate receptor function and methods of use thereof
EP2910637A1 (en) * 2008-05-20 2015-08-26 University of Florida Research Foundation, Inc. Vectors for delivery of light-sensitive proteins and methods of use
RU2374245C1 (ru) * 2008-08-22 2009-11-27 Андрей Александрович Иващенко Лиганд с широким спектром одновременной рецепторной активности, фармацевтическая композиция, способ ее получения и лекарственное средство
NZ602416A (en) * 2008-11-14 2014-08-29 Univ Leland Stanford Junior Optically-based stimulation of target cells and modifications thereto

Also Published As

Publication number Publication date
ZA201308824B (en) 2015-02-25
HUE047074T2 (hu) 2020-04-28
LT3029063T (lt) 2020-02-10
BR122022007044A8 (pt) 2022-11-01
CN103814045B (zh) 2017-05-31
US20140171376A1 (en) 2014-06-19
AU2012272505A1 (en) 2014-01-16
BR112013033028A2 (pt) 2017-01-31
CN103814045A (zh) 2014-05-21
EP2723767A1 (en) 2014-04-30
KR20140039281A (ko) 2014-04-01
CA2840458A1 (en) 2012-12-27
PL2723767T3 (pl) 2016-06-30
CA2840458C (en) 2020-09-22
BR112013033028A8 (pt) 2022-11-01
HRP20200004T1 (hr) 2020-05-15
BR122022007044B1 (pt) 2023-11-14
WO2012174674A1 (en) 2012-12-27
SI3029063T1 (sl) 2020-03-31
JP2014524903A (ja) 2014-09-25
US10112984B2 (en) 2018-10-30
AU2012272505B2 (en) 2017-03-02
RU2014101708A (ru) 2015-07-27
EP2723767B1 (en) 2016-01-06
RU2637367C2 (ru) 2017-12-04
EP2723767B8 (en) 2016-03-02
CN107383184A (zh) 2017-11-24
EP3029063A1 (en) 2016-06-08
ES2766398T3 (es) 2020-06-12
BR122022007044A2 (enExample) 2017-01-31
EP3029063B1 (en) 2019-10-16
PL3029063T3 (pl) 2020-05-18
PT3029063T (pt) 2020-01-22
DK3029063T3 (da) 2020-01-20
KR102008538B1 (ko) 2019-08-08

Similar Documents

Publication Publication Date Title
EP3029063B1 (en) Light-sensitive chimeric gpcr protein
US12343408B2 (en) AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
US8470790B2 (en) Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
US20200268647A1 (en) Method of enhancing delivery of therapeutic compounds to the eye
MX2010012592A (es) Vectores para la administracion de proteinas sensibles a la luz y metodos de uso de las mismas.
JP2019518073A (ja) Ｃｈｒｉｍｓｏｎを用いた光遺伝学的視覚回復
JP2025159109A (ja) 改変チャネルロドプシン
Tomita et al. 26 Strategies for Restoring Vision by Transducing a Channelrhodopsin Gene into Retinal Ganglion Cells
HK1220625B (en) A plasmin for use in enhancing delivery of therapeutic compounds to the eyes or for improving vision

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170801

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20170925

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171010

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171102

R150 Certificate of patent or registration of utility model

Ref document number: 6240067

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250